Urine drug test detection times in Australia vary by substance: cannabis 3–60 days depending on frequency of use; methamphetamine 2–5 days; cocaine metabolites 2–4 days; opioids 1–4 days; benzodiazepines 1–7 days. All workplace urine testing must comply with AS 4308:2023, which sets cut-off concentrations that determine what counts as a non-negative screen and a confirmed positive result. A positive urine test identifies prior use — it does not establish impairment at the time of testing.
Why detection windows matter — and why they are widely misunderstood
Most workplace drug and alcohol policies in Australia were written when urine testing was the only available option and the science was less understood. Many of those policies still conflate “positive test” with “impairment at work” — an error that creates legal exposure and produces unfair outcomes for workers.
Cannabis is the clearest example. A worker who smokes cannabis recreationally on a Saturday night, in a jurisdiction where it remains unlawful, is not impaired when they arrive for their Monday morning shift. But if that worker is tested on Monday, their urine sample will likely return a non-negative result — because cannabis metabolites (specifically THC-COOH) are fat-soluble and remain in urine for days to weeks after the acute effects have long resolved.
The detection window does not tell you when the person used the substance or whether they were impaired when they used it. It only tells you that, at some point before the test, a substance entered their system above the detection threshold. For employers making safety and employment decisions, that distinction has significant legal and clinical consequences.
Urine drug test detection windows by substance
The following windows apply to urine testing under AS 4308:2023 cut-off concentrations. Oral fluid (saliva) testing under AS 4760:2019 has substantially shorter detection windows for all substances and is a better indicator of recent use.
| Substance | Single use | Regular use | Chronic use | AS 4308:2023 screen cut-off |
|---|---|---|---|---|
| Cannabis (THC-COOH) | 3–7 days | 7–21 days | 30–60 days | 50 ng/mL |
| Methamphetamine | 2–4 days | 4–7 days | 5–7 days | 300 ng/mL |
| MDMA (ecstasy) | 2–4 days | 3–5 days | 5–7 days | 300 ng/mL |
| Cocaine metabolites | 2–4 days | 4–7 days | 7–14 days | 300 ng/mL |
| Heroin / morphine | 1–3 days | 3–5 days | 5–7 days | 300 ng/mL |
| Codeine | 1–3 days | 2–4 days | 3–5 days | 300 ng/mL |
| Benzodiazepines (short-acting) | 1–3 days | 3–7 days | 7–14 days | 200 ng/mL |
| Benzodiazepines (long-acting) | 3–7 days | 14–30 days | 30–60 days | 200 ng/mL |
Detection windows are population estimates. Individual variation in body mass, kidney function, hydration, and metabolic rate can shift windows by 30–50%. Long-acting benzodiazepines (diazepam, clonazepam) accumulate and clear slowly; detection windows for chronic users may exceed 30 days.
AS 4308:2023 and AS 4760:2019 — what the standards actually require
Workplace drug testing in Australia operates under two Australian Standards. Getting them confused is one of the most common compliance errors in employer drug and alcohol programs.
Procedures for specimen collection and the detection and quantitation of drugs of abuse in urine
Governs urine specimen collection, chain of custody, initial screening, and laboratory confirmation. Sets the cut-off concentrations that determine whether a specimen is “non-negative” on screening and “positive” on confirmation. A laboratory must achieve NATA accreditation to perform confirmation testing under this standard. The 2023 revision updated benzodiazepine panels and added specific provisions for the medical review officer (MRO) process.
Procedures for specimen collection and the detection and quantitation of drugs in oral fluid
Governs oral fluid (saliva) collection and testing — typically point-of-care devices plus laboratory confirmation. Oral fluid testing detects a much shorter window of recent use. The AS 4760:2019 cut-offs are calibrated for recent consumption: cannabis oral fluid is detected for 4–10 hours after use; methamphetamine for 24–48 hours. Many high-risk industries use oral fluid for post-incident and for-cause testing because of the tighter temporal relationship between result and use.
A workplace drug and alcohol policy that does not specify which standard applies to each test type is not compliant. An employer using an oral fluid device but referencing AS 4308:2023 cut-offs in their policy has a drafting error that will be identified in any legal challenge to a dismissal.
The legal framework — WHS Act, Fair Work Act, and Disability Discrimination Act
Three pieces of legislation shape how drug test results may lawfully be used in Australian workplaces. Each pulls in a slightly different direction, which is why drug testing policy requires careful calibration.
Work Health and Safety Act 2011 (model WHS Act)
Employers must eliminate or minimise risks so far as is reasonably practicable. A worker impaired by drugs or alcohol is a foreseeable risk to themselves and others — the employer has a positive duty to manage that risk. This is the basis for requiring pre-employment drug testing in safety-critical roles, for-cause testing following incidents, and random testing programs in high-risk industries (mining, transport, construction, oil and gas).
Fair Work Act 2009
Employment decisions following a positive drug test — including termination — must be procedurally fair and substantively justified. A dismissal based on a non-negative screen (not confirmed by laboratory) or without following the policy process set out in the enterprise agreement or employment contract is vulnerable to an unfair dismissal application. The Fair Work Commission has consistently found that procedural failures in drug test administration are sufficient grounds to overturn otherwise substantively justified dismissals.
Disability Discrimination Act 1992 (Cth)
Substance use disorder is a recognised disability under the DDA. An employer who dismisses a worker solely for returning a positive test, without considering whether the worker has an underlying dependency condition that constitutes a disability and whether reasonable adjustment (such as a rehabilitation program) is practicable, risks a disability discrimination complaint. This does not mean positive results cannot lead to employment consequences — it means the process must engage with the possibility of an underlying condition before reaching an adverse employment outcome.
What employers should do after a confirmed positive result
A confirmed positive result is the start of a process, not the end of one. Most errors in workplace drug testing outcomes happen in the steps after the result arrives.
Remove from safety-critical duties immediately
This is a safety step, not a disciplinary one. Document it as such. The worker should be stood down from safety-critical duties pending the process — this is consistent with the WHS duty of care and does not prejudge the outcome.
Engage the medical review officer (MRO) process
Under AS 4308:2023, a confirmed positive result should be reviewed by a medical review officer before an adverse outcome is reported to the employer. The MRO contacts the worker to identify any prescribed medications, medical conditions, or other clinical factors that may explain the result. This step is routinely skipped by non-compliant programs and is the single most common deficiency identified in Fair Work Commission hearings involving drug test dismissals.
Follow the policy process — precisely
Whether your policy specifies a show-cause letter, a disciplinary meeting, a right to a second test, or a union notification requirement — follow it exactly. Procedural deviation is a gift to any subsequent unfair dismissal claim. The substance of your case may be solid; the procedure determines whether it survives challenge.
Consider rehabilitation before dismissal
For a first positive result, and particularly where the worker has an otherwise clean record, many enterprise agreements and the general protections provisions of the Fair Work Act 2009 create an expectation that rehabilitation options will be offered before termination is reached. Document your consideration of rehabilitation, even if you ultimately conclude it is not appropriate.
Frequently asked questions
How long does cannabis stay detectable in a urine drug test in Australia?
For an occasional user (1–2 times per week), cannabis metabolites (THC-COOH) are typically detectable in urine for 3–7 days after last use at the AS 4308:2023 cut-off of 50 ng/mL. For a daily user, detection windows extend to 14–30 days. For a heavy chronic user (multiple times per day over months), the window can reach 45–60 days due to THC accumulation in fatty tissue. Urine drug tests under AS 4308:2023 detect past cannabis use — they cannot determine when use occurred or whether the worker was impaired at the time of testing.
What are the AS 4308:2023 cut-off concentrations for urine drug testing in Australia?
AS 4308:2023 (the current Australian standard for urine drug testing) sets initial screening cut-offs and laboratory confirmation cut-offs for each drug class. The screening cut-offs are: THC (cannabis) 50 ng/mL; cocaine metabolites 300 ng/mL; amphetamines (including methamphetamine) 300 ng/mL; opiates 300 ng/mL; benzodiazepines 200 ng/mL. A non-negative screen must be confirmed by laboratory GC-MS or LC-MS/MS at the confirmation cut-off before being reported as a positive result. A screen-only result is not a confirmed positive under the standard.
Can a worker be stood down immediately following a non-negative oral fluid test result under Australian law?
Under AS 4760:2019 (oral fluid testing) and most enterprise agreements and workplace drug and alcohol policies in Australia, a non-negative initial screen result is not a confirmed positive and should not be treated as one. The worker should be removed from safety-critical duties pending laboratory confirmation — this is prudent and legally defensible — but should not be subject to disciplinary action until a confirmed laboratory result is available. An employer who terminates employment on the basis of a non-negative screen alone faces significant exposure under the Fair Work Act 2009 for unfair dismissal.
Do urine drug test detection times differ for workplace testing versus roadside testing in Australia?
Yes, significantly. Roadside drug testing (RDT) in Australia uses oral fluid (saliva) under state-based road transport legislation. Oral fluid testing under AS 4760:2019 detects recent use — typically within 4–24 hours for most substances — and is specifically designed to identify current impairment risk. Workplace urine testing under AS 4308:2023 uses a different specimen and detects a much longer window of prior use, not current impairment. Cannabis detected in a workplace urine test at day 10 post-use would not be detected by a roadside oral fluid test at that same time. Employers sometimes conflate the two, leading to erroneous impairment conclusions from urine results.
Can a medical prescription protect a worker from a positive workplace drug test result in Australia?
A valid prescription is a significant clinical and legal factor, but it does not automatically invalidate a positive result or remove the employer's duty to manage safety risk. Under the Work Health and Safety Act 2011, the obligation to manage impairment risk at work exists regardless of whether a substance is prescribed. A worker prescribed opioids, benzodiazepines, or other impairing medications has an obligation to inform their employer or treating occupational physician of the potential for performance or safety impairment. The medical review officer (MRO) process under AS 4308:2023 exists to evaluate the clinical relevance of prescribed medications to a confirmed positive result before an outcome is reported to the employer.
What is the detection window for methamphetamine in a urine drug test?
Methamphetamine and amphetamine are typically detectable in urine for 2–5 days after a single-use episode at the AS 4308:2023 confirmation cut-off of 150 ng/mL. For regular users, the window extends to 5–7 days. Methamphetamine has a half-life of approximately 10–12 hours. At the standard 300 ng/mL screening cut-off, a single moderate dose may clear urine in as little as 24–48 hours in a well-hydrated individual. The oral fluid (saliva) detection window for methamphetamine is shorter — typically 24–48 hours at the AS 4760:2019 confirmation cut-off of 25 ng/mL.
Drug & Alcohol Testing — Employer Platform
OccuSpan's AS 4308:2023-compliant drug and alcohol testing program for Australian employers.
Pre-Employment Drug Testing Guide
When and how to include drug testing in pre-employment screening programs.
Fitness for Work Assessment
How fitness for work assessments relate to substance use and impairment in safety-critical roles.
Return to Work Management
Managing return to work pathways where substance use has been a contributing factor in injury.
OccuSpan
Drug and alcohol testing that meets the standard
OccuSpan’s drug and alcohol testing program is built to AS 4308:2023 and AS 4760:2019. Every result flows through the MRO process, chain-of-custody documentation is automated, and policy compliance is tracked against your enterprise agreement and WHS obligations.
See the drug & alcohol testing module